{
    "clinical_study": {
        "@rank": "132681", 
        "arm_group": [
            {
                "arm_group_label": "7.5 mg LY2541546 - IV", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 7.5 mg LY2541546 administered intravenously (IV)"
            }, 
            {
                "arm_group_label": "25 mg LY2541546 - IV", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 25 mg LY2541546 administered IV"
            }, 
            {
                "arm_group_label": "75 mg LY2541546 - IV", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 75 mg LY2541546 administered IV"
            }, 
            {
                "arm_group_label": "225 mg LY2541546 - IV", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 225 mg LY2541546 administered IV"
            }, 
            {
                "arm_group_label": "750 mg LY2541546 - IV", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 750 mg LY2541546 administered IV"
            }, 
            {
                "arm_group_label": "150 mg LY2541546 - SC", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 150 mg LY2541546 administered subcutaneous (SC)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single dose of placebo administered IV or SC"
            }, 
            {
                "arm_group_label": "225 mg LY2541546 - IV, OL", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 225 mg LY2541546 administered IV, open label (OL)"
            }, 
            {
                "arm_group_label": "750 mg LY2541546 - IV, OL", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 750 mg LY2541546 administered IV, OL"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if a single dose of LY2541546 has any side effects\n      on the body and to determine how long and how much LY2541546 stays in the bloodstream of the\n      body."
        }, 
        "brief_title": "A Study of LY2541546 in Healthy Postmenopausal Women", 
        "completion_date": {
            "#text": "June 2010", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy postmenopausal females, as determined by medical history and physical\n             examination\n\n          -  Body mass index (BMI) at screening between 19.0 and 32.0 kilograms per square meter\n             (kg/m^2), inclusive\n\n          -  Acceptable Clinical laboratory test results, blood pressure and heart rate\n\n          -  Have given written informed consent\n\n          -  Additional Inclusion Criterion for Participants in Open Label Groups:  Are currently\n             taking or recently discontinued (not more than 3 months prior to study randomization)\n             alendronate and have taken alendronate for at least 12 of the last 18 months\n\n        Exclusion Criteria:\n\n          -  Within 30 days of the initial dose of study drug, have received treatment with a drug\n             that has not received regulatory approval for any indication\n\n          -  Known allergies to LY2541546, its constituents, or related compounds\n\n          -  Persons who have previously participated in this study\n\n          -  History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,\n             endocrine, hematological, or neurological disorders\n\n          -  History of or high risk for adverse outcome from bleeding, for example, transient\n             ischemic attacks, cerebrovascular attacks, and ulcer disease\n\n          -  Paget's disease, parathyroid disease, or thyroid disease\n\n          -  Fracture of a long bone within 12 weeks of screening\n\n          -  Regular use of known drugs of abuse and/or positive findings on urinary drug\n             screening\n\n          -  Evidence of human immunodeficiency virus (HIV), hepatitis C, hepatitis B and/or\n             positive for anti-HIV antibodies, hepatitis C antibody, or hepatitis B surface\n             antigen\n\n          -  Current use of therapies for osteoporosis or use of hormone replacement therapy (HRT)\n             within the previous 12 months\n\n          -  Blood donation within the last month\n\n          -  Participants who have an average weekly alcohol intake that exceeds 14 units per week\n\n          -  Cigarette consumption of more than 10 cigarettes per day, or are unable or unwilling\n             to refrain from nicotine during Clinical Research Unit (CRU) confinement\n\n        Additional Exclusion Criterion for Participants in Double Blind Groups Only\n\n          -  Have received bisphosphonates during the previous 24 months.\n\n        Additional Exclusion Criterion for Participants in Open Label Groups\n\n          -  Have received intravenous bisphosphonates within the previous 18 months"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01742078", 
            "org_study_id": "11952", 
            "secondary_id": "I2M-MC-GSDA"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "7.5 mg LY2541546 - IV", 
                    "25 mg LY2541546 - IV", 
                    "75 mg LY2541546 - IV", 
                    "225 mg LY2541546 - IV", 
                    "750 mg LY2541546 - IV", 
                    "225 mg LY2541546 - IV, OL", 
                    "750 mg LY2541546 - IV, OL"
                ], 
                "description": "Administered IV", 
                "intervention_name": "LY2541546 - IV", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "150 mg LY2541546 - SC", 
                "description": "Administered SC", 
                "intervention_name": "LY2541546 - SC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Administered IV or SC", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Postmenopausal females", 
            "Volunteers"
        ], 
        "lastchanged_date": "December 4, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Evansville", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "47710"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "9", 
        "official_title": "A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2541546 in Healthy Postmenopausal Women", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with One or More Serious Adverse Event(s) (SAEs) considered by the Investigator to be Related to Study Drug Administration", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 through Day 85"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01742078"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration Curve Versus Time Curve from Time Zero to Infinity (AUC0-\u221e) of LY2541546", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 85"
            }, 
            {
                "measure": "Pharmacodynamics (PD): Lumbar Spine Bone Mineral Density", 
                "safety_issue": "No", 
                "time_frame": "Predose (Day 1) and Postdose (Day 29 and 85)"
            }, 
            {
                "measure": "Pharmacodynamic (PD): N-terminal Propeptide of Procollagen Type 1 (P1NP)", 
                "safety_issue": "No", 
                "time_frame": "Predose through Day 85"
            }, 
            {
                "measure": "Immunogenicity:  The Number of Participants with Anti-LY2541546 Antibodies", 
                "safety_issue": "No", 
                "time_frame": "Predose (Day 1) and Postdose (Day 29 and 85)"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}